Is CA-125 a Reliable Test for Endometriosis?
Many women hope for a simple blood test to settle the question. CA-125 is the one usually offered — and the one that most reliably disappoints.
Short answer. No — CA-125 is not reliable for diagnosing or ruling out endometriosis. It fails on both counts: it can be normal in significant disease (poor sensitivity) and raised by many harmless conditions like fibroids, ordinary ovulation and pelvic inflammation (poor specificity). A normal result doesn't reassure and a raised one doesn't confirm. There is no simple blood test that reliably diagnoses endometriosis — CA-125 has narrow uses, but this isn't one of them.
Why CA-125 fails as a diagnostic test
A good diagnostic test needs two properties, and CA-125 lacks both for endometriosis. Sensitivity — catching the disease when it is there — is poor: many women with significant endometriosis have entirely normal CA-125 levels. Specificity — being raised only by the target disease — is also poor: CA-125 rises in fibroids, ordinary ovulation, pelvic inflammation, pregnancy and numerous other benign situations, as well as in some cancers. A test that is often normal when disease is present and often raised when it is absent cannot reliably diagnose or exclude anything. Understanding this spares women false hope and false alarm alike, which is why honest endometriosis care is clear that no simple blood test currently does this job.
Source: ESHRE — endometriosis guideline: biomarkers.
What a CA-125 result actually tells you
Neither a high nor a low result answers the question most women are asking.
| Result | What it does — and doesn't — mean |
|---|---|
| Normal CA-125 | Does not rule out endometriosis, even significant disease |
| Raised CA-125 | Does not confirm it — many benign causes raise it |
| Any single value | Cannot diagnose or exclude endometriosis on its own |
| A very high value | Warrants evaluation for other causes, not endometriosis by default |
Learn more: Can Endometriosis Be Diagnosed Without a Laparoscopy?
Source: NICE — endometriosis: investigations.
What CA-125 is genuinely useful for
Dismissing CA-125 as a diagnostic test does not make it worthless — it simply has different jobs. Its established role is in the evaluation of ovarian masses, as one input among several helping to characterize a cyst, particularly where malignancy needs consideration. It can also occasionally have a role in monitoring in specific situations. What it is not is a screening or diagnostic test for endometriosis, and it should never be used to reassure a woman with typical symptoms that she is fine, nor to alarm one whose level is mildly raised for an entirely benign reason. Used within its real lane — mass characterization, not endometriosis diagnosis — it is a reasonable tool; used as a shortcut to diagnose or exclude the disease, it misleads in both directions.
| Appropriate use | Inappropriate use |
|---|---|
| Helping characterize an ovarian mass | Diagnosing endometriosis |
| One input alongside imaging | Ruling endometriosis out |
| Specific monitoring situations | Reassuring or alarming based on the level alone |
Patients also ask: Endometrioma vs Ovarian Cyst — How Do Doctors Tell the Difference?
At our clinic in Türkiye, we don't use CA-125 to diagnose or exclude endometriosis — it can't do either reliably, and we won't let a blood number override a woman's symptoms in either direction.
Second opinion. If a CA-125 result has been used to reassure or alarm you about endometriosis, an independent review can put it in proper context; you can request an online second opinion for endometriosis.
The performance figures
The numbers explain the verdict. Across studies, CA-125 detects endometriosis with sensitivity in the region of 50% at commonly used thresholds — meaning roughly half of affected women test normal — while specificity is better but still leaves many false positives from benign causes. Levels do rise with disease stage, so severe endometriosis is more likely to raise it than minimal disease, but that gradient does not rescue the test: a marker that misses half of cases and flags healthy women cannot serve as a diagnostic or screening tool for anyone.
Everything else that raises it
The list of benign causes is long enough to explain the specificity problem. Menstruation itself raises CA-125, which is why the timing of the blood draw matters and why testing during a period produces misleading results. Fibroids, ovarian cysts of every type, pelvic inflammatory disease, pregnancy and recent abdominal surgery all raise it. So do conditions outside the pelvis entirely: liver disease, heart failure, and any inflammation of the lining of the chest or abdomen. A raised value in a woman with any of these tells you about that condition, not about endometriosis.
The search for a better blood test
The field has looked hard and not yet found one. Dozens of candidate markers — inflammatory molecules, microRNAs, panels combining several proteins — have shown promise in initial studies and failed to hold up in validation. No blood test has yet achieved the accuracy needed for clinical use, and current guidelines recommend against using biomarkers to diagnose or exclude endometriosis. Research continues and a reliable test may eventually arrive; commercial tests marketed today as endometriosis blood screens are ahead of the evidence, and worth treating with skepticism.
Frequently Asked Questions
Sensitivity sits around 50% at common thresholds — roughly half of affected women test normal — with specificity limited by many benign causes. Those figures rule it out as a diagnostic or screening test.
Yes — menstruation itself raises CA-125, so a sample taken during a period is misleading. If it is being measured for another reason, timing outside menstruation gives a more interpretable value.
Not on that number alone. Fibroids, cysts, pelvic inflammation, pregnancy, recent surgery and even liver or heart conditions raise it. What matters is the imaging and the clinical picture it sits alongside.
Not currently. Many candidate markers have shown early promise and failed validation, and guidelines recommend against using biomarkers to diagnose or exclude the disease.
Most likely to help characterize an ovarian mass, which is its established role — one input alongside imaging where the nature of a cyst is being assessed. That use is appropriate; diagnosing endometriosis is not.
They are ahead of the evidence — none has demonstrated the accuracy required for clinical use. Money spent on them is better kept for expert imaging, which genuinely changes what is known.
CA-125 is the test women most hope will finally give them a yes or no — and the one I most often have to explain away. Normal doesn't clear you, raised doesn't convict you. I refuse to let a number that vague overrule what a woman is actually telling me about her body.
